Wyatt Technology Announces Executive Team Changes
Geofrey Wyatt has been named CEO and Clifford Wyatt named president of Wyatt Technology.
Wyatt Technology, a developer of instrumentation for absolute macromolecular and nanoparticle characterization, announced changes to its executive team on May 1, 2018.
Geofrey Wyatt was named chief executive office, and Clifford Wyatt was named president. Philip Wyatt, who founded the company almost 40 years ago, will become chairman of the board and take on a more passive role, the company reported in a press statement.
The company also announced that Michelle Chen was promoted to vice-president of analytical services and will join the executive team.
Source: Wyatt Technology
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
